Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Total Valuation
Lisata Therapeutics has a market cap or net worth of $45.25M. The enterprise value is $29.30M.
Market Cap$45.25M
Enterprise Value$29.30M
Share Statistics
Lisata Therapeutics has 9,032,291 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,032,291
Owned by Insiders10.53%
Owned by Institutions1.25%
Financial Efficiency
Lisata Therapeutics’s return on equity (ROE) is -1.12 and return on invested capital (ROIC) is -117.30%.
Return on Equity (ROE)-1.12
Return on Assets (ROA)-0.93
Return on Invested Capital (ROIC)-117.30%
Return on Capital Employed (ROCE)-1.24
Revenue Per Employee6.54K
Profits Per Employee-637.92K
Employee Count26
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lisata Therapeutics is ―. Lisata Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio95.05
PB Ratio1.09
Price to Fair Value1.09
Price to FCF-1.01
Price to Operating Cash Flow-2.73
PEG Ratio0.05
Income Statement
In the last 12 months, Lisata Therapeutics had revenue of 170.00K and earned -16.59M in profits. Earnings per share was -1.91.
Revenue170.00K
Gross Profit24.00K
Operating Income-18.21M
Pretax Income-17.55M
Net Income-16.59M
EBITDA-18.06M
Earnings Per Share (EPS)-1.91
Cash Flow
In the last 12 months, operating cash flow was -15.95M and capital expenditures -56.00K, giving a free cash flow of -16.00M billion.
Operating Cash Flow-15.95M
Free Cash Flow-16.00M
Free Cash Flow per Share-1.77
Dividends & Yields
Lisata Therapeutics pays an annual dividend of $0.31, resulting in a dividend yield of ―
Dividend Per Share$0.31
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.63
52-Week Price Change113.19%
50-Day Moving Average4.47
200-Day Moving Average2.89
Relative Strength Index (RSI)69.92
Average Volume (3m)34.52K
Important Dates
Lisata Therapeutics upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Lisata Therapeutics as a current ratio of 5.76, with Debt / Equity ratio of 0.00%
Current Ratio5.76
Quick Ratio5.76
Debt to Market Cap0.00
Net Debt to EBITDA0.88
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lisata Therapeutics has paid -962.00K in taxes.
Income Tax-962.00K
Effective Tax Rate0.05
Enterprise Valuation
Lisata Therapeutics EV to EBITDA ratio is -0.01, with an EV/FCF ratio of -0.01.
EV to Sales1.19
EV to EBITDA-0.01
EV to Free Cash Flow-0.01
EV to Operating Cash Flow-0.01
Balance Sheet
Lisata Therapeutics has $15.96M in cash and marketable securities with $0.00 in debt, giving a net cash position of $15.96M billion.
Cash & Marketable Securities$15.96M
Total Debt$0.00
Net Cash$15.96M
Net Cash Per Share$1.77
Tangible Book Value Per Share$1.68
Margins
Gross margin is 91.18%, with operating margin of -10711.18%, and net profit margin of -9756.47%.
Gross Margin91.18%
Operating Margin-10711.18%
Pretax Margin-10322.35%
Net Profit Margin-9756.47%
EBITDA Margin-10625.29%
EBIT Margin-10711.18%
Analyst Forecast
The average price target for Lisata Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast15.32%